Advertisement

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy

Published:November 12, 2015DOI:https://doi.org/10.1016/j.jaci.2015.10.005

      Background

      Although studies of oral immunotherapy (OIT) for food allergy have shown promise, treatment is frequently complicated by adverse reactions and, even when successful, has limited long-term efficacy because benefits usually diminish when treatment is discontinued.

      Objective

      We sought to examine whether the addition of omalizumab to milk OIT reduces treatment-related reactions, improves outcomes, or both.

      Methods

      This was a double-blind, placebo-controlled trial with subjects randomized to omalizumab or placebo. Open-label milk OIT was initiated after 4 months of omalizumab/placebo with escalation to maintenance over 22 to 40 weeks, followed by daily maintenance dosing through month 28. At month 28, omalizumab was discontinued, and subjects passing an oral food challenge (OFC) continued OIT for 8 weeks, after which OIT was discontinued with rechallenge at month 32 to assess sustained unresponsiveness (SU).

      Results

      Fifty-seven subjects (7-32 years) were randomized, with no significant baseline differences in age, milk-specific IgE levels, skin test results, or OFC results. At month 28, 24 (88.9%) omalizumab-treated subjects and 20 (71.4%) placebo-treated subjects passed the 10-g “desensitization” OFC (P = .18). At month 32, SU was demonstrated in 48.1% in the omalizumab group and 35.7% in the placebo group (P = .42). Adverse reactions were markedly reduced during OIT escalation in omalizumab-treated subjects for percentages of doses per subject provoking symptoms (2.1% vs 16.1%, P = .0005), dose-related reactions requiring treatment (0.0% vs 3.8%, P = .0008), and doses required to achieve maintenance (198 vs 225, P = .008).

      Conclusions

      In this first randomized, double-blind, placebo-controlled trial of omalizumab in combination with food OIT, we found significant improvements in measurements of safety but not in outcomes of efficacy (desensitization and SU).

      Key words

      Abbreviations used:

      APC (Antigen-presenting cell), CMA (Cow's milk allergy), MOIT (Milk oral immunotherapy), OFC (Oral food challenge), OIT (Oral immunotherapy), SCD (Successfully consumed dose), SPT (Skin prick test), SU (Sustained unresponsiveness)
      To read this article in full you will need to make a payment

      References

        • Boyce J.A.
        • Assa'ad A.
        • Burks A.W.
        • Jones S.M.
        • Sampson H.A.
        • Wood R.A.
        • et al.
        Guidelines for the diagnosis and management of food allergy in the united states: summary of the NIAID-sponsored expert panel report.
        J Allergy Clin Immunol. 2010; 126: 1105-1118
        • Sicherer S.H.
        Epidemiology of food allergy.
        J Allergy Clin Immunol. 2011; 127: 594-602
        • Wood R.A.
        • Sicherer S.H.
        • Vickery B.P.
        • Jones S.M.
        • Liu A.H.
        • Fleischer D.M.
        • et al.
        • The natural history of milk allergy in an observational cohort
        J Allergy Clin Immunol. 2013; 131: 805-812
        • Skripak J.M.
        • Matsui E.C.
        • Mudd K.
        • Wood R.A.
        The natural history of IgE-mediated cow's milk allergy.
        J Allergy Clin Immunol. 2007; 120: 1172-1177
        • Fleischer D.M.
        • Perry T.T.
        • Atkins D.
        • Wood R.A.
        • Burks A.W.
        • Jones S.M.
        • et al.
        Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study.
        Pediatrics. 2012; 130: e25-32
        • Boyano-Martinez T.
        • Garcia-Ara C.
        • Pedrosa M.
        • Diaz-Pena J.M.
        • Quirce S.
        Accidental allergic reactions in children allergic to cow's milk proteins.
        J Allergy Clin Immunol. 2009; 123: 883-888
        • Skripak J.M.
        • Nash S.D.
        • Rowley H.
        • Brereton N.H.
        • Oh S.
        • Hamilton R.G.
        • et al.
        A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy.
        J Allergy Clin Immunol. 2008; 122: 1154-1160
        • Longo G.
        • Barbi E.
        • Berti I.
        • Meneghetti R.
        • Pittalis A.
        • Ronfani L.
        • et al.
        Specific oral tolerance induction in children with very severe cow's milk-induced reactions.
        J Allergy Clin Immunol. 2008; 121: 343-347
        • Meglio P.
        • Giampietro P.G.
        • Gianni S.
        • Galli E.
        Oral desensitization in children with immunoglobulin E-mediated cow's milk allergy—follow-up at 4 yr and 8 months.
        Pediatr Allergy Immunol. 2008; 19: 412-419
        • Keet C.A.
        • Frischmeyer-Guerrerio P.A.
        • Thyagarajan A.
        • Schroeder J.T.
        • Hamilton R.G.
        • Boden S.
        • et al.
        The safety and efficacy of sublingual and oral immunotherapy for milk allergy.
        J Allergy Clin Immunol. 2012; 129 (e1-5): 448-455
        • Staden U.
        • Rolinck-Werninghaus C.
        • Brewe F.
        • Wahn U.
        • Niggemann B.
        • Beyer K.
        Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction.
        Allergy. 2007; 62: 1261-1269
        • Keet C.A.
        • Seopaul S.
        • Knorr S.
        • Narisety S.
        • Skripak J.
        • Wood R.A.
        Long-term follow-up of oral immunotherapy for cow's milk allergy.
        J Allergy Clin Immunol. 2013; 132: 737-739.e6
        • Burks A.W.
        • Jones S.M.
        • Wood R.A.
        • Fleischer D.M.
        • Sicherer S.H.
        • Lindblad R.W.
        • et al.
        Oral immunotherapy for treatment of egg allergy in children.
        N Engl J Med. 2012; 367: 233-243
        • Syed A.
        • Garcia M.A.
        • Lyu S.C.
        • Bucayu R.
        • Kohli A.
        • Ishida S.
        • et al.
        Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).
        J Allergy Clin Immunol. 2014; 133: 500-510
        • Narisety S.D.
        • Frischmeyer-Guerrerio P.A.
        • Keet C.A.
        • Gorelik M.
        • Schroeder J.
        • Hamilton R.G.
        • et al.
        A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
        J Allergy Clin Immunol. 2015; 135 (e1-6): 1274-1282
        • Gorelik M.
        • Narisety S.D.
        • Guerrerio A.L.
        • Chichester K.L.
        • Keet C.A.
        • Bieneman A.P.
        • et al.
        Suppression of the immunologic response to peanut during immunotherapy is often transient.
        J Allergy Clin Immunol. 2015; 135: 1283-1292
        • Casale T.B.
        • Busse W.W.
        • Kline J.N.
        • Ballas Z.K.
        • Moss M.H.
        • Townley R.G.
        • et al.
        Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
        J Allergy Clin Immunol. 2006; 117: 134-140
        • Massanari M.
        • Nelson H.
        • Casale T.
        • Busse W.
        • Kianifard F.
        • Geba G.P.
        • et al.
        Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.
        J Allergy Clin Immunol. 2010; 125: 383-389
        • Nadeau K.C.
        • Schneider L.C.
        • Hoyte L.
        • Borras I.
        • Umetsu D.T.
        Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy.
        J Allergy Clin Immunol. 2011; 127: 1622-1624
        • Schneider L.C.
        • Rachid R.
        • LeBovidge J.
        • Blood E.
        • Mittal M.
        • Umetsu D.T.
        A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.
        J Allergy Clin Immunol. 2013; 132: 1368-1374
        • van der Heijden F.L.
        • van Neerven R.J.
        • Kapsenberg M.L.
        Relationship between facilitated allergen presentation and the presence of allergen-specific IgE in serum of atopic patients.
        Clin Exp Immunol. 1995; 99: 289-293
        • van Neerven R.J.
        • van Roomen C.P.
        • Thomas W.R.
        • de Boer M.
        • Knol E.F.
        • Davis F.M.
        Humanized anti-IgE mAb Hu-901 prevents the activation of allergen-specific T cells.
        Int Arch Allergy Immunol. 2001; 124: 400-402
        • Wilcock L.K.
        • Francis J.N.
        • Durham S.R.
        IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy.
        Immunol Allergy Clin North Am. 2006; 26 (viii-ix): 333-347
        • Prussin C.
        • Griffith D.T.
        • Boesel K.M.
        • Lin H.
        • Foster B.
        • Casale T.B.
        Omalizumab treatment downregulates dendritic cell FcεRI expression.
        J Allergy Clin Immunol. 2003; 112: 1147-1154
        • Berin M.C.
        Mucosal antibodies in the regulation of tolerance and allergy to foods.
        Semin Immunopathol. 2012; 34: 633-642
        • Ford L.S.
        • Bloom K.A.
        • Nowak-Wegrzyn A.H.
        • Shreffler W.G.
        • Masilamani M.
        • Sampson H.A.
        Basophil reactivity, wheal size, and immunoglobulin levels distinguish degrees of cow's milk tolerance.
        J Allergy Clin Immunol. 2013; 131 (e1-3): 180-186
        • Hamilton R.G.
        • Marcotte G.V.
        • Saini S.S.
        Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.
        J Immunol Methods. 2005; 303: 81-91
        • Leung D.Y.
        • Sampson H.A.
        • Yunginger J.W.
        • Burks Jr., A.W.
        • Schneider L.C.
        • Wortel C.H.
        • et al.
        Effect of anti-IgE therapy in patients with peanut allergy.
        N Engl J Med. 2003; 348: 986-993
        • Savage J.H.
        • Courneya J.P.
        • Sterba P.M.
        • Macglashan D.W.
        • Saini S.S.
        • Wood R.A.
        Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy.
        J Allergy Clin Immunol. 2012; 130: 1123-1129.e2
        • Sampson H.A.
        • Leung D.Y.
        • Burks A.W.
        • Lack G.
        • Bahna S.L.
        • Jones S.M.
        • et al.
        A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy.
        J Allergy Clin Immunol. 2011; 127: 1309-1310.e1
        • Novak N.
        • Kraft S.
        • Bieber T.
        Unraveling the mission of FcepsilonRI on antigen-presenting cells.
        J Allergy Clin Immunol. 2003; 111: 38-44
        • Maurer D.
        • Ebner C.
        • Reininger B.
        • Fiebiger E.
        • Kraft D.
        • Kinet J.P.
        • et al.
        The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation.
        J Immunol. 1995; 154: 6285-6290